Physician profile
Gary Owen Bean
NPI 1760452312
$8,120.26
in general payments reported to CMS, 2019-2025
49 companies · $32.64 in 2025
The $32.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $1,063 · 2021: $1,121 · 2022: $1,628 · 2023: $1,226 · 2024: $1,278 · 2025: $32.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229 · Consulting Fee: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.66 |
| Consulting Fee | $308.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,002.10 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $834.56 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $831.65 | 2019-2024 | Qulipta, Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.67 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Chugai Pharmaceutical Co., LTD. | $500.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $423.71 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $394.72 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $379.01 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $365.02 | 2019-2023 | Spravato |
| Becton, Dickinson and Company | $308.33 | 2024 | |
| Glaxosmithkline, LLC. | $299.72 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $291.56 | 2021-2025 | Proclaim, Freestyle Libre 3, Lamitrode |
| Amarin Pharma, INC. | $186.74 | 2019-2021 | |
| Astellas Pharma US INC | $142.48 | 2019-2024 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $140.89 | 2019-2023 | Seglentis |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.